oncbrain — oncology meeting digest

ESAONA

Sat, 30 May 2026 00:00:00 GMT

[Challenges SOC] Intracranial ORR 95.5% vs 79.6% (p=0.0004), iPFS HR 0.46 favoring asandeutertinib over osimertinib in 1L EGFR+ NSCLC with brain mets. Eligible: 1L EGFR-mutated NSCLC with active brain metastases

Wait or Treat — NCT05236946 (Upfront vs Delayed Brain RT in Oncogene-mutated NSCLC)

Fri, 29 May 2026 00:00:00 GMT

[Challenges SOC] Upfront brain RT halves icPD (HR 0.35, p<0.001) but OS numerically favors delayed (HR 1.45, 2yr 60% vs 48%) in EGFR/ALK+ mNSCLC. Eligible: Metastatic NSCLC, EGFR or ALK mutant, completely asymptomatic BM, ECOG 0-2

EORTC 22922/10925

Thu, 21 May 2026 00:00:00 GMT

[Challenges SOC] 20yr OS HR 1.00 (null): BC mortality reduced HR 0.82 but non-BC deaths increased HR 1.26, offsetting benefit. Eligible: Stage I-III breast, node-positive or central/medial tumor, median age 54, post-s

LS-SCLC 54 Gy Hyperfractionated RT

Wed, 20 May 2026 00:00:00 GMT

[Challenges SOC] mOS 60.7 vs 39.5mo (HR 0.55, p=0.003) favoring 54 Gy hyperfractionated RT in LS-SCLC; no added toxicity. Eligible: LS-SCLC, ECOG 0–1, age 18–70, chemo-naive or ≤1 prior platinum-etoposide cycle

ePLND vs PSMA PET staging in prostate cancer (AUA 2026)

Tue, 19 May 2026 00:00:00 GMT

[Challenges SOC] 47.7% of LN mets outside ePLND template; PSMA PET NPV ~96%; RCTs no consistent BCR benefit from routine dissection. Eligible: Localized prostate cancer, intermediate to high risk, primary staging pre-RP

PEACE 2

Mon, 18 May 2026 00:00:00 GMT

[Challenges SOC] Pelvic RT did not improve cPFS vs prostate-only RT in VHR localized prostate cancer (HR 0.81, p=0.088). Eligible: VHR localized prostate (≥2: Gleason ≥8, T3-T4, PSA ≥20), N0M0 on conventional im

TORPEdO (CRUK/18/010)

Mon, 18 May 2026 00:00:00 GMT

[Challenges SOC] IMPT showed no HR-QoL benefit vs IMRT at 12 months in OPSCC; UW-QoL scores similar across arms to 24 months. Eligible: Oropharyngeal SCC requiring definitive concurrent CRT with bilateral neck treatm

EORTC IM-MS (22922/10925)

Sun, 17 May 2026 00:00:00 GMT

[Challenges SOC] 20-yr OS null (HR 1.00, p=0.967); BCM benefit offset by non-BCM excess; pN0: no benefit. Eligible: Stage I-III BC, node-positive or pN0, adjuvant IM-MS RT decision

DBCG RT Natural

Sun, 17 May 2026 00:00:00 GMT

[Challenges SOC] 9.8% 4-yr LR without PBI vs 1.5% with PBI in pT1N0 low-risk elderly breast conservation; stopped early per pre-specified threshold. Eligible: ≥60y, pT1N0, ER+ ≥10%, HER2-normal, grade 1-2, unifocal post-lumpectomy